At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-blind Randomized, Sequential Treatment Group, Placebo-controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-striatal Function Of 2 Doses Of Pf-02545920 In Subjects With Early Huntington's Disease
In Brief
A Phase 2 clinical trial evaluating PF-02545920 and Placebo for Huntington's Disease. Completed, enrolled 37 participants across 1 site.
Detailed Summary
This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.
Study Details
Timeline
Interventions
* Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28. * Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals. * Treatment for 28 days.
\- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals. Dosing for 28 days.
* 5mg dose * Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals. * Dosing for 28 days.
* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals. * Dosing for 28 days.